📰 Clinically Utilized News
Clinically Utilized News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinically Utilized. Real-time updates on events, politics, business and more.
September 25, 2023
 Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...
September 25, 2023
TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...
September 25, 2023
Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...
July 21, 2023
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and...
December 12, 2022
Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...
December 12, 2022
COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...
December 11, 2022
Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage
December 11, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...
November 3, 2022
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignanciesFour oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) la...